Idenix Pharmaceuticals Inc

Type: Company
Name: Idenix Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.idenix.com/
First reported 5 hours ago - Updated 5 hours ago - 1 reports

Must-know: The Baupost Group’s 2Q14 positions

Overview: The Baupost Group’s 2Q14 positions (Part 1 of 6)Baupost Group’s 2Q14 positionsSeth Klarman’s Baupost Group is one of the best-performing hedge fund managers of all time. It has generated $21.5 billion in returns over its history. In this series, ... [Published Yahoo! Finance - 5 hours ago]
First reported 5 hours ago - Updated 5 hours ago - 1 reports

2014 has potential to exceed milestone year of 2009 for M&A action

Pharma M&A action so far this year has been intense--so intense that if it keeps up the pace it could match the uber years of 2008 and 2010, maybe even the record year of 2009.According to an H1 report from the data gearheads at EvaluatePharma, $87 billion ... [Published FiercePharma - 5 hours ago]
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Micron Technology, Inc. (MU), Idenix Pharmaceuticals Inc (IDIX) ViaSat, Inc. (VSAT): Billionaire Seth Klarman’s Top Picks

Founded in 1982,  Baupost Group is one of the largest hedge funds in the world and has generated an average annual return of 19% since its inception. The fund’s equity portfolio is mainly invested in technology and health care stocks. Energy companies ... [Published InsiderMonkey.com - 7 hours ago]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Why Wall Street Is Not Bearish On Merck

Bidness Etc explores sell side’s views on Merck stock after the company beat revenue and earnings estimates for its second quarterPage 1 of 2Click Ticker to See live coverageNone of the analysts covering Merck & Co., Inc. ( MRK ) are bearish due to the ... [Published Bidness Etc - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Alzheon Appoints Renowned Industry Leader, Jean-Pierre Sommadossi, PhD, to Board of Directors

By a News Reporter-Staff News Editor at Biotech Week Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced that it has appointed Jean-Pierre Sommadossi, PhD, to the company's Board of Directors. ... [Published Pharmacy Choice - Aug 20 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

3 Reasons Merck & Co., Inc.'s Stock Could Rise

For investors lucky enough to have jumped into Merck ( NYSE: MRK     ) in 2009 at the tail end of the Great Recession you've seen an appreciation in your shares of near 100%. However, for longer-term shareholders Merck has been a source of great fru ... [Published Motley Fool Discussion Boards - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Merck Is Banking On Pembrolizumab And Hepatitis C...

Pembrolizumab Development OverviewMerck has channeled some of its funds for developing immuno-oncology drugs. MK-3475 (pembrolizumab) is Merck's investigational PD-1 specific monoclonal antibody for the treatment of advanced malignancy. The drug essentially ... [Published Nasdaq - Aug 18 2014]
First reported Aug 15 2014 - Updated Aug 16 2014 - 1 reports

Gilead fends off Roche as hep C heavyweights fight for blockbuster rights

Gilead Sciences ($GILD) convinced an panel of arbitrators that rival Roche ($RHHBY) had no legitimate claims on Sovaldi, its record-setting hepatitis C treatment, but the antiviral pioneer still faces patent spats with a host of challengers looking to ... [Published FierceBiotech - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

UPDATE 1-Achillion's hepatitis C drug shows promise in trial

(Adds details, analysts' comments on data, share movement)Aug 15 (Reuters) - Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending ... [Published CNBC - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Tracking Seth Klarman's Baupost Group Holdings - Q2 2014 Update

Summary Seth Klarman’s US long portfolio increased a whopping ~48% from $4.14B to $6.14B this quarter as Idenix Pharmaceuticals and Micron Technology posted outsized returns. Baupost Group added eBay Inc. this quarter while dropping BP plc. The US ... [Published Seeking Alpha - Aug 15 2014]
First reported Aug 10 2014 - Updated Aug 11 2014 - 2 reports

Merck – Preparing For The Next Move

  Merck & Co. Inc. (MRK) -NYSE   Lately, Merck was under the spot light after Idenix Pharmaceuticals deal, paying $3.85 Billion more than triple Idenix’s market capitalization before the. The post Merck – Preparing For The Next Move appeared first ... [Published Chimera Research Group - Proceed With Confidence - Aug 11 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 10 reports

Merck completes tender offer to acquire Idenix

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) at a purchase price of $24.50 ... [Published European Pharmaceutical Review - Aug 05 2014]

Quotes

...Sommadossi. "I look forward to sharing my insights and experiences with the strong leadership team at Alzheon as the company advances its lead candidate, ALZ-801, as well as building other promising clinical assets in Alzheon's portfolio."
"This class of drug (ACH-3102) is not as unique an asset as ACH-3422, that's the nuc. If they have positive data, then they are going to have a very high likelihood of takeout just like Idenix" FBR Capital Markets & Co analyst Andrew Berens told Reuters
...milestones, we remain focused on execution of the broader clinical development strategy for our HCV portfolio," Deshpande said in a statement. "We expect that Phase I proof-of-concept results with ACH-3422 will be reported during the fall of this year, which we anticipate will lead to the start of a Phase II combination program to evaluate our proprietary doublet regimen for an 8-week, or potentially shorter, treatment regimen for HCV that will begin before the end of 2"
...The fund continues to hold well over a quarter of the AUM in cash. Seth Klarman's distinct investment style is elaborated in his 1991 book " Margin of Safety: Risk-averse value investing strategies for the thoughtful investor ": the book is out-of-print and copies sell for a huge premium."

More Content

All (179) | News (103) | Reports (0) | Blogs (56) | Audio/Video (0) | Fact Sheets (1) | Press Releases (17)
sort by: Date | Relevance
Must-know: The Baupost Group’s 2Q14 positions [Published Yahoo! Finance - 5 hours ago]
2014 has potential to exceed milestone year of ... [Published FiercePharma - 5 hours ago]
Micron Technology, Inc. (MU), Idenix Pharmaceut... [Published InsiderMonkey.com - 7 hours ago]
Why Wall Street Is Not Bearish On Merck [Published Bidness Etc - Aug 21 2014]
Alzheon Appoints Renowned Industry Leader, Jean... [Published Pharmacy Choice - Aug 20 2014]
3 Reasons Merck & Co., Inc.'s Stock Could Rise [Published Motley Fool Discussion Boards - Aug 19 2014]
Merck Is Banking On Pembrolizumab And Hepatitis... [Published Nasdaq - Aug 18 2014]
Gilead fends off Roche as hep C heavyweights fi... [Published FierceBiotech - Aug 15 2014]
Corporate Executive of the Year: Kenneth Frazie... [Published Black Enterprise - Aug 15 2014]
UPDATE 1-Achillion's hepatitis C drug shows pro... [Published CNBC - Aug 15 2014]
Achillion shoulders its way into the hep C race... [Published FierceBiotech - Aug 15 2014]
Tracking Seth Klarman's Baupost Group Holdings ... [Published Seeking Alpha - Aug 15 2014]
Seth Klarman's The Baupost Group Buys eBay, Sun... [Published Guru Focus - Aug 14 2014]
Klarman's Baupost Group 13F Shows New Stakes in... [Published Industrial Info Financials - Aug 14 2014]
Prem Watsa Buys Idenix, Questcor, Navient; Sell... [Published Value Walk - Aug 14 2014]
Prem Watsa Buys 4 New Stocks [Published Yahoo! Finance - Aug 14 2014]
Baupost Group Dumps Entire Stake in Idenix Phar... [Published Value Walk - Aug 13 2014]
Will Intercept Pharmaceuticals Be Acquired? [Published Bidness Etc - Aug 12 2014]
Enanta Pharmaceuticals Is Simply Too Cheap To I... [Published BioPortfolio - Aug 11 2014]
Enanta Pharmaceuticals Is Simply Too Cheap To I... [Published Seeking Alpha - Aug 11 2014]
Merck: Should You Buy It? [Published Seeking Alpha - Aug 11 2014]
Merck – Preparing For The Next Move [Published Chimera Research Group - Proceed With Confidence - Aug 11 2014]
Merck Completes Tender Offer to Acquire Idenix [Published PharmaAsia - Aug 10 2014]
Baupost Discloses 14.06% Stake In Veritiv Corpo... [Published Value Walk - Aug 10 2014]
Alzheon Elects Jean-Pierre Sommadossi, PhD to I... [Published Individual.com - Aug 08 2014]
Gilead: A Growth Story [Published Seeking Alpha - Aug 06 2014]
General American Investors Reports Filing of Sh... [Published Individual.com - Aug 06 2014]
Ukraine Tension Prominent As Dow Suffers Triple... [Published Benzinga.com - Aug 05 2014]
Ukraine Tension Prominent As Dow Suffers Triple... [Published MoneyShow.com - Aug 05 2014]
HollyFrontier Second-Quarter Earnings: What To ... [Published Bidness Etc - Aug 05 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Merck – Preparing For The Next Move [Published Chimera Research Group - Proceed With Confidence - Aug 11 2014]
  Merck & Co. Inc. (MRK) -NYSE   Lately, Merck was under the spot light after Idenix Pharmaceuticals deal, paying $3.85 Billion more than triple Idenix’s market capitalization before the. The post Merck – Preparing For The Next Move appeared first ...
Merck Completes Tender Offer to Acquire Idenix [Published EON Business - Aug 05 2014]
WHITEHOUSE STATION, N.J.--(EON: Enhanced Online News)--Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. at a purchase price of $24.50 per share. ...
Merck Completes Tender Offer to Acquire Idenix [Published Business Wire Professional Services News - Aug 05 2014]
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. at a purchase price of $24.50 per share. ...
Merck Completes Tender Offer to Acquire Idenix [Published Business Wire Health News - Aug 05 2014]
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. at a purchase price of $24.50 per share. ...
Biotechnology Stocks Technical Review -- Resear... [Published PR Newswire: Financial Services - Jul 11 2014]
LONDON, July 11, 2014 /PRNewswire/ --On Thursday, July 10, 2014, the NASDAQ Composite ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished the session at 16,915.07, down 0.42% and the S&P 500 closed at 1,964.68, down 0.41%. During ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Idenix Pharmaceuticals Reports Second Quarter a... [Published GlobeNewswire: Advertising News - Jul 31 2014]
The Zacks Analyst Blog Highlights: AbbVie, Gile... [Published Financial Services - Jun 17 2014]
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announc... [Published Financial Services - Jun 13 2014]
SHAREHOLDER ALERT: Pomerantz LLP Investigates C... [Published Financial Services - Jun 13 2014]
Study Results, Updated Organization Structures,... [Published Financial Services - Jun 05 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.